XORIDRONO

Serial Number 99127135
686

Registration Progress

Application Filed
Apr 8, 2025
Under Examination
Approved for Publication
Nov 18, 2025
Published for Opposition
Nov 18, 2025
Registered

Trademark Image

XORIDRONO

Basic Information

Serial Number
99127135
Filing Date
April 8, 2025
Published for Opposition
November 18, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
686
Status Date
Nov 18, 2025
Application
Pending
Classes
005

Rights Holder

CivicaScript, LLC

16
Address
2912 Executive Parkway, Suite 300
Lehi, UT 84043

Ownership History

CivicaScript, LLC

Original Applicant
16
Lehi, UT

CivicaScript, LLC

Owner at Publication
16
Lehi, UT

Legal Representation

Attorney
Joshua G. Gigger

USPTO Deadlines

All Deadlines Cleared

All 1 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

14 events
Date Code Type Description Documents
Nov 18, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Nov 18, 2025 PUBO A PUBLISHED FOR OPPOSITION Loading...
Nov 12, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Oct 23, 2025 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Oct 17, 2025 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Oct 17, 2025 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Oct 17, 2025 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Sep 9, 2025 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Sep 9, 2025 GNRT F NON-FINAL ACTION E-MAILED Loading...
Sep 9, 2025 CNRT R NON-FINAL ACTION WRITTEN Loading...
Sep 4, 2025 DOCK D ASSIGNED TO EXAMINER Loading...
Apr 8, 2025 MAFR O APPLICATION FILING RECEIPT MAILED Loading...
Apr 8, 2025 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Apr 8, 2025 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical products for the treatment of cancer; pharmaceutical products for the treatment of colorectal cancer; pharmaceutical products for the treatment of breast cancer; Pharmaceutical products for the treatment of gastric, esophageal and gastroesophageal junction cancer; pharmaceutical products for the treatment of pancreatic cancer

Classification

International Classes
005